Eli Lilly's Timing of the FDA Filing of Its Next Weight Loss Drug Is Now Official and Novo Nordisk Has a Problem Eli Lilly's latest announcement has sent shockwaves through the pharmaceutical industry.
The company's next generation weight loss medication, retatrutide, is poised to shake up the market in a big way.
With its triple pathway approach to addressing obesity, this new medicine is not just a worthy successor to Eli Lilly's best selling Zepbound – it's a game changer.